BMC health services research · 2026
Safety and implementation of a regional hospital-at-home model: a retrospective observational study from Denmark.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hägi-Pedersen Mai-Britt, Blomberg Stig Nikolaj, Hendriksen Ole Mazur, Al-Janaby Ihab Ibrahim Rassoul, Christensen Helle Collatz
Аннотация
OBJECTIVES: To describe the patient population, care pathways, and short-term safety outcomes of a regional hospital-at-home model in Region Zealand, Denmark, between 2022 and 2024, and to explore variation in outcomes by diagnosis and referral source.
DESIGN: Retrospective observational study using registry-based data and internal monitoring records.
SETTING: A publicly funded, cross-sectoral hospital-at-home service coordinated centrally and delivered via municipal nurses and mobile treatment units.
PARTICIPANTS: We included 2,511 patients with a median age of 72 years (IQR 60-80). Patients generally presented with substantial comorbidity and represented a broad, clinically diverse population.
MAIN OUTCOME MEASURES: Length of stay, unplanned hospital contacts during treatment or within 24 h after planned completion, 30-day readmissions, and 30-day survival.
RESULTS: The median length of stay increased from 5.1 days in 2022 to 7.3 days in 2024. Rates of unplanned hospital contacts remained stable (27.0-31.1%), whereas 30-day readmission rates declined from 11.0% to 7.0% over the study period. Thirty-day survival remained consistently high (91.6-92.4%). Infectious diseases were the most frequent diagnostic category (43-47%). Outcomes varied by diagnosis and referral source, with longer treatment durations observed among patients with orthopaedic and chronic conditions.
CONCLUSIONS: Hospital-level care delivered in patients' homes was implemented on a regional scale with acceptable short-term outcomes across a clinically complex and socially diverse patient population, including individuals living alone. The variation in outcomes across diagnostic groups underscores the importance of flexible, diagnosis-informed care pathways and structured cross-sectoral organisation in hospital-at-home models.
CLINICAL TRIAL NUMBER: Not applicable.
DESIGN: Retrospective observational study using registry-based data and internal monitoring records.
SETTING: A publicly funded, cross-sectoral hospital-at-home service coordinated centrally and delivered via municipal nurses and mobile treatment units.
PARTICIPANTS: We included 2,511 patients with a median age of 72 years (IQR 60-80). Patients generally presented with substantial comorbidity and represented a broad, clinically diverse population.
MAIN OUTCOME MEASURES: Length of stay, unplanned hospital contacts during treatment or within 24 h after planned completion, 30-day readmissions, and 30-day survival.
RESULTS: The median length of stay increased from 5.1 days in 2022 to 7.3 days in 2024. Rates of unplanned hospital contacts remained stable (27.0-31.1%), whereas 30-day readmission rates declined from 11.0% to 7.0% over the study period. Thirty-day survival remained consistently high (91.6-92.4%). Infectious diseases were the most frequent diagnostic category (43-47%). Outcomes varied by diagnosis and referral source, with longer treatment durations observed among patients with orthopaedic and chronic conditions.
CONCLUSIONS: Hospital-level care delivered in patients' homes was implemented on a regional scale with acceptable short-term outcomes across a clinically complex and socially diverse patient population, including individuals living alone. The variation in outcomes across diagnostic groups underscores the importance of flexible, diagnosis-informed care pathways and structured cross-sectoral organisation in hospital-at-home models.
CLINICAL TRIAL NUMBER: Not applicable.